Recombinant SARS-CoV-2 Nucleocapsid antibody (AA 1-419) (Fc Tag)
-
- Target See all SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) Antibodies
- SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
- Antibody Type
- Recombinant Antibody
- Fragment
- scFv fragment
-
Binding Specificity
- AA 1-419
-
Reactivity
- SARS Coronavirus-2 (SARS-CoV-2)
-
Host
-
HEK-293 Cells
-
Clonality
- Chimeric
-
Conjugate
- This SARS-CoV-2 Nucleocapsid antibody is conjugated to Fc Tag
-
Application
- ELISA, Western Blotting (WB), Colloidal Gold Immunochromatography Assay (GICA)
- Specificity
- Mouse scFv fusion with human IgG1 Fc
- Characteristics
- Recombinant anti-SARS-CoV-2 Nucleoprotein Mouse ScFv is expressed from 293 cells (HEK293) with a human IgG1 Fc tag on C-terminal.
- Purification
- Affinity-chromatography
- Immunogen
- Recombinant Human Novel Coronavirus Nucleoprotein (N) (1-419aa)
- Clone
- 1A6
- Isotype
- IgG1
- Top Product
- Discover our top product SARS-CoV-2 N Primary Antibody
-
-
- Application Notes
-
ELISA 1:10000-1:50000
WB 1:500-1:5000
GICA 1:1000-1:50000 - Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
- 50 % Glycerol, 0.01M PBS, pH 7.4, 0.03 % Proclin 300
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- -20 °C,-80 °C
- Storage Comment
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
-
Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell®. ..." in: Vaccines, Vol. 11, Issue 4, (2023) (PubMed).
: "
-
Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell®. ..." in: Vaccines, Vol. 11, Issue 4, (2023) (PubMed).
-
- Target
- SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
- Alternative Name
- SARS-CoV-2 Nucleocapsid Protein (SARS-CoV-2 N Products)
- Synonyms
- nucleocapsid phosphoprotein antibody, N antibody
- Target Type
- Viral Protein
- UniProt
- P0DTC9
-